Jake Chabon, PhD

Dr. Jake Chabon is the Chief Executive Officer and Chief Scientific Officer of Foresight Diagnostics, which he co-founded with academic oncologists in 2020. He is a molecular biologist and bioinformatic scientist with more than 50 peer-reviewed publications, including manuscripts published in Nature and Nature Biotechnology related to Foresight’s liquid biopsy technology (PhasED-Seq™), and over 7,000 citations attributed to his work.

Along with his co-founders, Jake has scaled Foresight Diagnostics from its initial seed funding to now a post-Series B, 90+ person company with a fully operational and automated sequencing laboratory. Under Jake’s leadership, Foresight has raised $86MM in VC funding and has forged partnerships with over 25 academic medical centers and pharmaceutical companies. His strategic focus on research and evidence generation have led to the company’s first prospective clinical trial in partnership with Allogene Therapeutics in 2024 to develop an MRD-based In Vitro Diagnostic to guide therapy selection for patients with large cell lymphoma. In addition to Jake’s scientific accomplishments, his professional recognitions include: 2024 EY Entrepreneur of the Year finalist for Mountain West, 2023 Dealmakers Award honoree, and the 2023 Rising Star Award from the Colorado Biosciences Association.

Prior to founding Foresight, Jake’s research focused on using cancer genomics to inform more personalized treatment strategies for patients with cancer. He has extensive experience with next-generation sequencing (NGS) assay development with an emphasis on developing noninvasive cancer detection methods and applying these methods to better understand mechanisms of response and resistance to cancer therapies.

Jake completed his Ph.D. and postdoctoral training at Stanford University under the co-mentorship of Dr. Maximilian Diehn and Dr. Ash Alizadeh, with whom he co-founded Foresight Diagnostics.